{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"13.2","value":"10.7"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"9.9","value":"6.8"}]}],"title":"BICR: DoR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"9.9","value":"8.3"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"6.6","value":"5.6"}]}],"title":"Investigator: DoR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"OG001","title":"Physician's Choice"}],"paramType":"MEDIAN","populationDescription":"Duration of response was assessed in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years","title":"Duration of Response in Participants With HER2-low Breast Cancer (All Patients)","type":"SECONDARY","unitOfMeasure":"months"}